“To find a therapy that's all encompassing, that manages all of this in a long-term fashion, low-dose vaginal estrogen is the preferred treatment,” says Ekene Enemchukwu, MD, MPH, FACS, URPS. While ...

PROSTOX ultra test predicts late-grade GU toxicity in prostate cancer patients post-radiation, with an AUC of 0.762. The test's sensitivity and specificity were 0.576 and 0.948, respectively, in the ...

A panelist discusses how benign prostatic hyperplasia (BPH) treatment has evolved to include a spectrum of minimally invasive and surgical interventions, ranging from emerging technologies like ...

"A lot of people are using [single-use ureteroscopes] nowadays, and part of it is because it really enhances our ability to provide guaranteed care, because we don't have to rely on the reusability of ...

“When I talk to physicians outside of urology, as well as within urology, much of the hesitation with using Cost Plus Drugs is that it seems complicated to use, when in reality, the process is ...

Gepotidacin, 177Lu-PSMA-617, and durvalumab received FDA approvals, marking significant advancements in urology treatment paradigms. UGN-102's NDA decision for LG-IR-NMIBC is expected by June 13, 2025 ...

"This study was an investigator initiated study, and what they wanted to do was a randomized trial for large prostates, so 80 to 180 grams, between Aquablation and prostate enucleation," says Naeem ...

Sixty percent of patients with baseline UUI experienced complete resolution at one year post-surgery, independent of sling type. De novo UUI was observed in 11% of patients, with colpocleisis ...

"We demonstrate that patients with metastatic disease stayed on therapy longer—a median of 9 months vs 7 months for the non-metastatic patients," says Rana R. McKay, MD, FASCO. Overall, data from the ...

"This is another tool in our armamentarium to treat muscle-invasive bladder cancer and represents an advance compared to where we've been over the past few decades," says Matthew D. Galsky, MD. The ...

The IRA caps Medicare Part D out-of-pocket costs at $2000 annually, significantly reducing financial toxicity for cancer patients. Allowing Medicare to negotiate drug prices may increase access to ...

UroLift patients demonstrated superior recovery outcomes, including higher satisfaction and improved sexual function, compared to Rezūm patients. The study showed significant differences in ...